The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

Part of paid clinical trials in Charlottesville, Virginia.

Sponsor
University of Virginia
Study ID
NCT07298915
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Obesity & Overweight

Eligibility Criteria

Sex
ALL
Age
30 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tirzepatide — DRUG
    Participants will take tirzepatide under the care of their primary care provider for 16 weeks
  • Exercise — BEHAVIORAL
    Participants will perform a combination of aerobic and resistance training for 16 weeks

Study Details

This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures

Key Dates

Start date
Aug 31, 2026
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Exercise
    Participants will perform aerobic and resistance exercise while taking monthly tirzepatide for 16 weeks
  • Active Comparator: Standard Care
    Participants will take monthly Tirzepatide under the care of their primary care provider for 16 weeks

Primary Outcome Measure

Weight [ Time Frame: Baseline and 16 Weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of VirginiaCharlottesvilleVirginia22901
Damon L Swift, Ph.D.
(434) 924-1436
Damon L Swift, Ph.D. (PRINCIPAL_INVESTIGATOR)
Catherine Varney, DO (SUB_INVESTIGATOR)
Jay Hertel, Ph.D. (SUB_INVESTIGATOR)
Sibylle Kranz, Ph.D. (SUB_INVESTIGATOR)

Find similar trials in Charlottesville, VA

By research site
University of Virginia· Charlottesville, VA

Related Studies